|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-10-2
|
|
pubmed:abstractText |
To identify clinical factors predictive of treatment outcome after high-dose chemotherapy (HDC) for Hodgkin's disease and to develop a prognostic model for progression-free and overall survival.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1083-8791
|
|
pubmed:author |
pubmed-author:AntinJJ,
pubmed-author:AntmanKK,
pubmed-author:AultKK,
pubmed-author:AyashLL,
pubmed-author:BiererBB,
pubmed-author:ChurchillW HWH,
pubmed-author:EderJ PJP,
pubmed-author:EickhoffCC,
pubmed-author:EliasAA,
pubmed-author:FerrariBB,
pubmed-author:FreiEE3rd,
pubmed-author:GaynesLL,
pubmed-author:GillilandGG,
pubmed-author:GuinanEE,
pubmed-author:IbrahimJJ,
pubmed-author:KadinMM,
pubmed-author:MauchPP,
pubmed-author:MazanetRR,
pubmed-author:McCauleyMM,
pubmed-author:ParsonsSS,
pubmed-author:RimmI JIJ,
pubmed-author:SchnipperLL,
pubmed-author:SchwartzGG,
pubmed-author:TeplerII,
pubmed-author:WheelerCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-106
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9267670-Adult,
pubmed-meshheading:9267670-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9267670-Carmustine,
pubmed-meshheading:9267670-Combined Modality Therapy,
pubmed-meshheading:9267670-Cyclophosphamide,
pubmed-meshheading:9267670-Disease-Free Survival,
pubmed-meshheading:9267670-Dose-Response Relationship, Drug,
pubmed-meshheading:9267670-Etoposide,
pubmed-meshheading:9267670-Female,
pubmed-meshheading:9267670-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9267670-Hodgkin Disease,
pubmed-meshheading:9267670-Humans,
pubmed-meshheading:9267670-Male,
pubmed-meshheading:9267670-Multivariate Analysis,
pubmed-meshheading:9267670-Prognosis,
pubmed-meshheading:9267670-Risk Factors,
pubmed-meshheading:9267670-Survival Rate,
pubmed-meshheading:9267670-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
|
|
pubmed:affiliation |
Division of Hematology Beth Israel Hospital, Boston, MA 02214, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
